Ensoma Announces $85 Million Financing And Agreement To Acquire Twelve Bio To Advance Portfolio Of In Vivo Engineered Cellular Medicines
Ensoma Announces $85 Million Financing And Agreement To Acquire Twelve Bio To Advance Portfolio Of In Vivo Engineered Cellular Medicines
01/05/23, 2:04 PM
Location
bostonMoney raised
$85 million
Industry
biotechnology
health care
Investors
Mirae Asset, Solasta Ventures, Catalio Capital Management, Qatar Investment Authority, Alexandria Venture Investments, Takeda Ventures, Inc., Viking Global Investors, Cormorant Asset Management, F Prime Capital, 5 Am Ventures, Arix Bioscience And 5 Am Ventures
Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the completion of an $85 million financing. Proceeds will enable Ensoma to advance the development of its EngeniousTM in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications. The company also announced it has entered into a definitive agreement to acquire Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology.
Company Info
Location
451 d street
boston, massachusetts, united states
Additional Info
Ensoma is developing curative medicines through precision in vivo cellular engineering. Our platform combines class-leading proprietary base editing and high-efficiency gene integration systems with high-capacity virus-like particles to provide one-time and durable genetic medicines in a simple outpatient procedure. We are focused on in vivo engineering of hematopoietic stem cells to address genetic diseases, immune disorders and cancer. Ensoma is supported by top-tier investors and a passionate team committed to a bold, global vision for genomic medicines. Ensoma is based in Boston.